We are live on ! Find out more
NXTC icon

NextCure
NXTC

38 hedge funds and large institutions have $7.38M invested in NextCure in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

0.2% less ownership

Funds ownership: 4.77% → 4.57% (-0.2%)

16% less funds holding

Funds holding: 45 → 38 (-7)

44% less capital invested

Capital invested by funds: $13.1M → $7.38M (-$5.75M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
38
Holders Change
-7
Holders Change %
-15.56%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
9
Reduced
9
Closed
7
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
P
Pfizer
New York
+$318K
2
CCC
Cable Car Capital
California
+$39.9K
3
Citigroup
Citigroup
New York
+$22.3K
4
Citadel Advisors
Citadel Advisors
Florida
+$8.79K
5
XT
XTX Topco
Cayman Islands
+$3.27K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$217K
2
LFCM
Long Focus Capital Management
Puerto Rico
-$143K
3
BlackRock
BlackRock
New York
-$126K
4
PLC
Peapod Lane Capital
New York
-$102K
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$83K

NXTC Hedge Fund Activity: Q1 2025 in Review

38 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q1 2025, worth a combined $7.38M — down 44% from $13.1M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of NXTC and 0 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 9 added.

The largest buyer was Pfizer, adding an estimated $318K. The largest seller was Tang Capital Management, cutting an estimated $217K.

  • 38 institutional investors held NextCure (NXTC) as of Q1 2025, down from 45 in Q4 2024.
  • Funds reported $7.38M of NextCure stock for Q1 2025, down 44% quarter-over-quarter.
  • 0 funds opened new NextCure positions in Q1 2025 and 7 closed out, a net change of -7 holders.
  • The largest NextCure buyer in Q1 2025 was Pfizer, an estimated $318K added.
  • The largest NextCure seller in Q1 2025 was Tang Capital Management, an estimated $217K sold.

Based on aggregated 13F filings for Q1 2025.